Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, general and administrative expenses

Restructuring and employee severance

Amortization and other acquisition-related costs

Impairments and (gain)/loss on disposal of assets, net

Litigation (recoveries)/charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cardinal Health

Cordis develops and manufactures medical devices for diagnostics and interventional procedures to treat patients suffering from coronary and peripheral vascular diseases.On October 4, 2015, Cardinal Health announced that it has completed the acquisition of Johnson & Johnson's Cordis business for $1.944 billion.

Cordis

Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The firm operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical, and laboratory products. The company was founded by Robert D. Walter in 1979 and is headquartered in Dublin, OH.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Cardinal Health reports strong Q3 results, focuses on Pharma growth

Cardinal Health's Q3 results demonstrated strong performance in the Pharma segment, while the Medical segment faced challenges. The company raised its guidance for the year and emphasized the importance of Red Oak Sourcing in maintaining market dynamics. Looking ahead, the company is focused on executing its medical improvement plan and maximizing shareholder value.

Cardinal Health reports stable Q2 growth, eyes Pharma segment

Cardinal Health's Q2 2023 performance showcased stability and growth in the Pharma segment, with a return to profitability in the Medical segment.
The company's strategic focus on executing key priorities and driving shareholder value creation is evident in its financial results.
Challenges such as international freight costs and supply chain headwinds are being addressed, while opportunities in COVID therapies, pricing strategy, and growth investments are being pursued.
Overall, Cardinal Health's revised outlook and strong performance in key segments position it for continued growth and financial success.

Cardinal Health reports robust Q3 earnings, eyes biosimilars for growth

Cardinal Health delivered strong financial performance in Q3 2023, driven by robust growth in the Pharma segment.
While facing challenges in the Medical segment, the company remains focused on mitigating inflation and maximizing shareholder value.
With a positive outlook on future growth opportunities, Cardinal Health aims to address cost pressures and drive profitability.

Cardinal Health achieves record results, raises guidance for fiscal '24

Cardinal Health's strong performance in Q4 and fiscal year 2023, coupled with strategic initiatives and guidance raise, position the company for continued growth and success.
Challenges such as inflation mitigation and cost pressures are being addressed, while opportunities in organic growth and strategic investments pave the way for future profitability.
The company's focus on advancing Pharma, executing the Medical Improvement Plan, and maximizing shareholder value creation underscores its commitment to sustained growth and value creation.

Cardinal Health reports strong Q1 earnings, raises guidance for FY24

Cardinal Health's Q1 2024 earnings call showcased robust performance, with profit growth in both Pharma and Medical segments. The company raised EPS guidance, demonstrated strong cash flow generation, and emphasized customer service and shareholder value creation. Challenges include managing margins, nonoperating items, and commodity price impacts, while opportunities lie in healthcare sector growth, innovation, and market dynamics.

Cardinal Health reports robust Q2 earnings, raises EPS guidance

Cardinal Health's Q2 performance reflects strong revenue growth, improved cash flow, and raised EPS guidance, supported by strategic acquisitions and growth initiatives.
While facing challenges from nonrecurring adjustments and SG&A growth, the company remains focused on core businesses and driving future growth opportunities.
With a positive outlook on market-driven growth, cost management, and strategic priorities, Cardinal Health aims to sustain its momentum and deliver value to shareholders.

Cardinal Health reports robust Q3 earnings, eyes growth opportunities ahead

Cardinal Health's Q3 performance reflects strong financial results and strategic progress across key segments, with raised guidance for fiscal '24 and '25.
The company faces challenges such as managing customer transitions and inflationary impacts but is well-positioned to capitalize on growth opportunities.
By focusing on cost optimization, strategic partnerships, and customer-centric solutions, Cardinal Health aims to drive sustained growth and profitability.
Investments in technology, brand growth, and operational efficiency underscore Cardinal Health's commitment to delivering value to shareholders and customers.

Cardinal Health excels in fiscal '24, raises guidance for '25

Cardinal Health's strong performance in fiscal year '24, highlighted by record financial results and strategic progress, positions the company for continued success.
Despite challenges such as market dynamics and customer transitions, the company's raised guidance for fiscal year '25 underscores confidence in future growth.
By capitalizing on strengths like revenue growth in key segments and making strategic investments, Cardinal Health is poised to navigate challenges and seize opportunities for sustained growth.

Cardinal Health reports strong Q1 performance and raises fiscal guidance

Cardinal Health's Q1 performance showed strength in Pharma and Specialty Solutions despite revenue decrease.
Challenges in GMPD segment and nuclear supply disruptions are being addressed for minimal impact.
Opportunities lie in continued cost reductions, growth normalization, and operational improvements.
Overall, Cardinal Health is well-positioned to navigate challenges and capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cardinal Health (CAH) shares hit a new all-time intraday high Friday as the healthcare products provider posted better-than-expected results and raised its outlook even as it took a financial hit from the ending of a big contract.

Cardinal Health Stock Hits All-Time High as Existing Customers Power Results

Cardinal Health, Inc. (NYSE:CAH ) Q1 2025 Earnings Conference Call November 1, 2024 8:30 AM ET Company Participants Matt Sims - Vice President, Investor Relations Jason Hollar - Chief Executive Officer Aaron Alt - Chief Financial Officer Conference Call Participants Lisa Gill - JPMorgan Michael Cherny - Leerink Partners Erin Wright - Morgan Stanley Eric Percher - Nephron Research Allen Lutz - Bank of America Kevin Caliendo - UBS Eric Coldwell - Baird George Hill - Deutsche Bank Stephanie Davis - Barclays Elizabeth Anderson - Evercore ISI Daniel Grosslight - Citi Charles Rhyee - TD Cowen Stephen Baxter - Wells Fargo Operator Hello, and welcome to the First Quarter Fiscal Year 2025 Cardinal Health, Incorporated Earnings Conference Call. My name is George, and I'll be your coordinator for today's event.

Cardinal Health, Inc. (CAH) Q1 2025 Earnings Call Transcript

Cardinal Health's first-quarter fiscal 2025 results benefit from solid Pharmaceutical and Specialty Solutions growth. However, OptumRx contract expiry hurts sales.

CAH Stocks Gains on Q1 Earnings & Sales Beat and Raised '25 EPS View

The headline numbers for Cardinal (CAH) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Here's What Key Metrics Tell Us About Cardinal (CAH) Q1 Earnings

Cardinal Health (CAH) came out with quarterly earnings of $1.88 per share, beating the Zacks Consensus Estimate of $1.64 per share. This compares to earnings of $1.73 per share a year ago.

Cardinal Health (CAH) Q1 Earnings and Revenues Beat Estimates

Cardinal Health raised its 2025 adjusted profit forecast on Friday as strong demand for costly specialty medicines and branded drugs drove sales at its pharmaceuticals unit, sending the shares of the company up nearly 4% in premarket trading.

Cardinal Health lifts annual profit outlook on strength in specialty medicines unit

Revenue decreased 4% to $52.3 billion; revenue increased 15% excluding the impact of the previously communicated large customer contract expiration GAAP 1 operating earnings were $568 million; GAAP diluted EPS was $1.70 Non-GAAP operating earnings increased 12% to $625 million, driven by significant growth in Pharmaceutical and Specialty Solutions segment profit Non-GAAP diluted EPS increased 9% to $1.88 Fiscal year 2025 non-GAAP EPS guidance2 raised to $7.75 to $7.90, from $7.55 to $7.70 DUBLIN, Ohio , Nov. 1, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported first quarter fiscal year 2025 revenue of $52.3 billion, a decrease of 4% from the first quarter of fiscal year 2024. First quarter revenue increased 15% excluding the impact of the previously communicated large customer contract expiration.

Cardinal Health Reports First Quarter Fiscal Year 2025 Results and Raises Fiscal Year 2025 Outlook

New facility in Boylston increases U.S. warehouse capacity and expands specialized handling capabilities DUBLIN, Ohio , Oct. 29, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today the grand opening of its new distribution center in Boylston, Massachusetts, supporting its U.S. Medical Products and Distribution business. The facility provides healthcare customers in Massachusetts, New Hampshire, Rhode Island, Maine, Vermont and Eastern Connecticut with modernized operations and expanded capacity, as well as specialized handling capabilities for products with strict storage requirements, available early 2025.

Cardinal Health celebrates medical product distribution center grand opening in Massachusetts

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Cardinal (CAH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.

Exploring Analyst Estimates for Cardinal (CAH) Q1 Earnings, Beyond Revenue and EPS

In the most recent trading session, Cardinal Health (CAH) closed at $110.87, indicating a -0.02% shift from the previous trading day.

Cardinal Health (CAH) Stock Sinks As Market Gains: Here's Why

Cardinal Health, Inc. CAH is scheduled to report  fiscal first-quarter  2025 results on Nov. 1, before the opening bell.

Cardinal Health to Report Q1 Earnings: What's in Store?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Cardinal Health (CAH) is a Strong Value Stock

Here's Why Cardinal Health (CAH) is a Strong Momentum Stock

In the closing of the recent trading day, Cardinal Health (CAH) stood at $111.92, denoting a -0.52% change from the preceding trading day.

Cardinal Health (CAH) Stock Dips While Market Gains: Key Facts

Cardinal Health and T2 Biosystems announce an agreement selecting the former to sell direct-from-blood diagnostics for the rapid detection of sepsis-causing pathogens.

CAH Stock May Gain Following the Distribution Deal With T2 Biosystems

CAH gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.

Reasons to Retain Cardinal Health Stock in Your Portfolio Now

CAH is set to acquire Oncology Network for $1.115 billion, expanding its oncology offerings while supporting community-based cancer care across 10 states.

Cardinal Health Stock Likely to Gain From the Acquisition of ION

DUBLIN, Ohio , Sept. 24, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release first-quarter financial results for its fiscal year 2025 on November 1, prior to the opening of trading on the New York Stock Exchange.

Cardinal Health to Announce First-Quarter Results for Fiscal Year 2025 on November 1

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Cardinal Health (CAH) Stock Undervalued Right Now?

Cardinal Health on Friday agreed to acquire Integrated Oncology Network, an independent community oncology network, for $1.12 billion in cash.

Cardinal Health to acquire Integrated Oncology Network for $1.12 billion

Transaction demonstrates Cardinal Health's continued strategic investment in specialty and oncology, underscores commitment to independent community healthcare providers  Accelerates the development of Navista oncology practice alliance , adding more than 100 providers at more than 50 community-based sites delivering broad-reaching oncology and urology care across 10 states DUBLIN, Ohio , Sept. 20, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that it has entered into a definitive agreement to acquire Integrated Oncology Network (ION), a physician-led independent community oncology network, for $1.115B in cash.

Cardinal Health to acquire Integrated Oncology Network, a physician-led independent community oncology network

Cardinal Health (CAH) reachead $110.76 at the closing of the latest trading day, reflecting a -0.58% change compared to its last close.

Cardinal Health (CAH) Stock Falls Amid Market Uptick: What Investors Need to Know

Dublin, Sept. 19, 2024 (GLOBE NEWSWIRE) -- The "Bioactive Dressings Market by Product (Collagen, Alginate, Chitosan, Skin Substitute), Property (Antimicrobial, Non-Antimicrobial), Application (Chronic Wounds (Diabetic Foot, Pressure Ulcers), Acute Wounds (Surgical, Burns))- Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering. The global bioactive dressings market is projected to reach USD 5.8 billion by 2029 from USD 3.5 billion in 2024, at a CAGR of 10.5% during the forecast period.

Bioactive Dressings - Comprehensive Global and Regional Market Forecast to 2029 - Featuring Strategical Analysis of 3M, Smith+Nephew, Cardinal Health, Braun, Molnlycke Health Care, Convatec & More

Cardinal Health and Telix announce an agreement selecting the former as a commercial radiopharmaceutical distributor to supply finished unit doses of Telix's Zircaix.

CAH Stock May Gain Following the Distribution Agreement With Telix

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

News for Cardinal Health Stock (CAH)